Biotech entity
pharma is the sole category represented across all 1 tracked stories. Galectin Therapeutics, Inc. is most often covered alongside Faisal Ghiath Sukhtian, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Galectin Therapeutics, Inc., all published on August 16, 2026.
Last mentioned: Aug 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Galectin Therapeutics, Inc. is most often covered alongside Faisal Ghiath Sukhtian, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Galectin Therapeutics, Inc., all published on August 16, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Galectin Therapeutics, Inc.. Shared-story counts are live from our verified record — not editorial picks.
For biotech and pharma professionals, two Nasdaq micro-cap companies missed earnings, but insider trades reveal divergent internal outlooks: Oncobiologics directors bought $5.16M while Galectin insiders sold $438K.
Source: themarketsdaily.com · tickerreport.com
Galectin Therapeutics, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
